JP2024534806A5 - - Google Patents
Info
- Publication number
- JP2024534806A5 JP2024534806A5 JP2024510298A JP2024510298A JP2024534806A5 JP 2024534806 A5 JP2024534806 A5 JP 2024534806A5 JP 2024510298 A JP2024510298 A JP 2024510298A JP 2024510298 A JP2024510298 A JP 2024510298A JP 2024534806 A5 JP2024534806 A5 JP 2024534806A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- gpc3
- cancer
- monoclonal antibody
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163235093P | 2021-08-19 | 2021-08-19 | |
| US63/235,093 | 2021-08-19 | ||
| PCT/US2022/040931 WO2023023354A2 (en) | 2021-08-19 | 2022-08-19 | Methods for detection of membrane bound glypican-3 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024534806A JP2024534806A (ja) | 2024-09-26 |
| JP2024534806A5 true JP2024534806A5 (https=) | 2025-08-27 |
Family
ID=85241111
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024510298A Pending JP2024534806A (ja) | 2021-08-19 | 2022-08-19 | 膜結合型グリピカン３の検出方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250085287A1 (https=) |
| EP (1) | EP4388010A4 (https=) |
| JP (1) | JP2024534806A (https=) |
| KR (1) | KR20240112375A (https=) |
| CN (1) | CN118451104A (https=) |
| AU (1) | AU2022331350A1 (https=) |
| CA (1) | CA3229705A1 (https=) |
| IL (1) | IL310866A (https=) |
| MX (1) | MX2024002121A (https=) |
| WO (1) | WO2023023354A2 (https=) |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1674111T1 (sl) * | 2004-07-09 | 2011-02-28 | Chugai Pharmaceutical Co Ltd | Protitelo proti glipikanu 3 |
| ME02345B (me) * | 2007-07-17 | 2016-08-31 | Squibb & Sons Llc | MONOKLONSKA ANTlTELA PROTIV GLIPIKANA-3 |
| EP2699603B1 (en) * | 2011-04-19 | 2016-03-02 | The United States of America As Represented by the Secretary Department of Health and Human Services | Human monoclonal antibodies specific for glypican-3 and use thereof |
| BR112014020826A8 (pt) * | 2012-02-24 | 2017-09-19 | Stem Centrx Inc | Anticorpo que se liga especificamente a um epítopo, ácido nucleico, vetor ou célula hospedeira, conjugado de fármaco anticorpo, composição farmacêutica compreendendo o referido anticorpo, uso do mesmo, kit e método de preparação do conjugado |
| US9926377B2 (en) * | 2014-05-22 | 2018-03-27 | Genentech, Inc. | Anti-GPC3 antibodies and immunoconjugates |
| TW201713700A (zh) * | 2015-05-27 | 2017-04-16 | 台灣泰福生技股份有限公司 | 抗ｇｌｙｐｉｃａｎ-３抗體及其用於診斷及治療癌症之用途 |
| ES2883240T3 (es) * | 2015-08-03 | 2021-12-07 | Cafa Therapeutics Ltd | Anticuerpo contra glipicano-3 y aplicación del mismo |
| MX2019008221A (es) * | 2017-01-10 | 2019-12-09 | Univ Yamaguchi | Anticuerpo anti-gpc3. |
| AR114112A1 (es) * | 2018-02-15 | 2020-07-22 | Seattle Genetics Inc | Anticuerpos de glipicano 3 y conjugados de los mismos |
| EP3762030A4 (en) * | 2018-03-09 | 2022-01-05 | Phanes Therapeutics, Inc. | ANTI-CD73 ANTIBODIES AND USES THEREOF |
-
2022
- 2022-08-19 WO PCT/US2022/040931 patent/WO2023023354A2/en not_active Ceased
- 2022-08-19 CN CN202280069477.8A patent/CN118451104A/zh active Pending
- 2022-08-19 CA CA3229705A patent/CA3229705A1/en active Pending
- 2022-08-19 AU AU2022331350A patent/AU2022331350A1/en active Pending
- 2022-08-19 US US18/684,672 patent/US20250085287A1/en active Pending
- 2022-08-19 IL IL310866A patent/IL310866A/en unknown
- 2022-08-19 MX MX2024002121A patent/MX2024002121A/es unknown
- 2022-08-19 JP JP2024510298A patent/JP2024534806A/ja active Pending
- 2022-08-19 EP EP22859236.6A patent/EP4388010A4/en active Pending
- 2022-08-19 KR KR1020247009119A patent/KR20240112375A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110799539B (zh) | 抗4-1bb抗体及其制备和使用方法 | |
| RU2430112C2 (ru) | Композиции и способы диагностики и лечения опухоли | |
| JP2019527553A5 (https=) | ||
| JP2020522261A5 (https=) | ||
| IL261666B2 (en) | Binding proteins and methods of use thereof | |
| CN110536903A (zh) | 抗ox40抗体及其用途 | |
| JP2022532173A5 (https=) | ||
| JP2013502913A5 (https=) | ||
| JP2022533538A5 (https=) | ||
| JP2022523710A5 (https=) | ||
| JP2022527151A5 (https=) | ||
| JP2021517152A5 (https=) | ||
| CA3223687A1 (en) | Neutralizing antibodies to the .alpha.v.beta.8 integrin complex for immunotherapy | |
| JP2020534012A5 (https=) | ||
| WO2023131193A1 (zh) | 靶向人b7-h3分子的人源化单克隆抗体及其应用 | |
| WO2023025315A1 (zh) | 抗b7-h3抗体、其制备方法及用途 | |
| JP2020509995A (ja) | 抗ヒトｔｉｍ−３抗体およびその使用方法 | |
| WO2023040940A1 (zh) | Pvrig/tigit结合蛋白联合免疫检查点抑制剂用于治疗癌症 | |
| JP2023510429A5 (https=) | ||
| JP2025507938A (ja) | 抗ｐｄ－ｌ２抗体 | |
| JP2009544574A5 (https=) | ||
| US8974786B2 (en) | Humanized antibodies to CA215 | |
| CN112805297B (zh) | 抗人类pd-l1抗体及其用途 | |
| EP4534562A1 (en) | Bispecific antibody and application thereof | |
| EP4032908A1 (en) | Anti-pd-l1 antibody and pharmaceutical use thereof |